Clinical Trial Begins for Novel Natural Killer Cell Therapy

Cincinnati Children’s is one of only a few centers in the nation to test a novel therapy that uses cytokine-induced memory-like natural killer cells from haploidentical donors to treat AML. This study is open to patients ages 12 to 45 years with relapsed or refractory AML who have not undergone bone marrow transplantation.